摘要
The authors regret that there are some compound structure errors and misplacement of Ref.Nos.in the article due to the mistake of copying and pasting in the process of assembling figures and negligence in the proofreading.Although it does not affect the conclusion,it is obvious errors.The authors have now modified as below.The authors apologize for any inconvenience caused to the journal and readers.1.Ref.23 should be replaced with‘Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes:ROS1 or NTRK fusions or increased MET or AXL activity.ClinicalTrails.
